Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic and orthopedic markets. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic or orthopedic industry newsletters.

Ophthalmic Orthopedic

Recently Added ophthalmic

2/21/2020
CataractNewsletterOphthalmicSurgical
Company is Focused on Implementing Office-Based Cataract Surgery as Advanced as ASC Procedure

Proponents of office-based surgery (OBS) view it as an opportunity to reduce the financial burden of cataract surgery on Medicare and insurance groups, while simultaneously offering surgeons more c...

2/21/2020
GlaucomaMeetingNewsletterOphthalmic
Qlaris Bio Wins Perfect Pitch Award at Glaucoma 360

Qlaris Bio, Inc., raised its profile at the 2020 Glaucoma 360 meeting, winning the Perfect Pitch Award, chosen by meeting attendees as the startup in which they would be most willing to invest. Thu...

2/21/2020
BreakingMeetingOphthalmic
Coronavirus Outbreak Pushes APAO Congress in China Back to August

The Asia-Pacific Academy of Ophthalmology has postponed its 2020 congress in Xiamen, China, due to the COVID-19 coronavirus outbreak. The congress will now take place Aug. 5-9 at the same site, Xia...

2/21/2020
BreakingOphthalmicPharma
Alcon Gains FDA Approval of OTC Pataday Through Rx-to-OTC Switch Process

Alcon will launch two versions of nonprescription Pataday on March 2 in the US after gaining FDA approval Feb. 14. The company’s spinoff from Novartis in 2019 included the rights to switch specifie...

2/21/2020
AtlasCataractNewsletterOphthalmicSurgical
New Cataract Atlas Identifies Location of Premium IOLs and High-Volume Surgeons

The metro areas of New York, Los Angeles, Dallas, and Chicago account for 14 percent of the population over 60 in the US. However, on a per capita share basis, most of the metro areas in Florida st...

2/21/2020
GlaucomaNewsletterOphthalmicPharma
Glaucoma Drug Revenue Falls in 2019 Despite Debut of New Products

The revenue from major, branded glaucoma drugs fell 5.4 percent in 2019 from 2018’s total, despite the launches of four new proprietary drugs since 2017. Increased competition from generics weighed...

2/21/2020
BreakingEarningsIOLOphthalmic
Bausch Health Reports Revenue of $2.22 Billion in Q4-2019 and $8.60 Billion in 2019

Bausch Health reported Feb. 19 that Q4-2019 revenue totaled $2.22 billion, an increase of 5 percent over $2.12 billion in Q4-2018. Total revenue for 2019 was $8.60 billion, an increase of 3 percent...

2/21/2020
BreakingEarningsOphthalmicPharmaRetina
Regeneron’s Net Sales of Eylea in the US Increase 11 Percent in Q4-2019

Regeneron’s US net sales of Eylea were $1.222 billion in Q4-2019 and $4.644 billion for the full year, compared with $1.079 billion in Q4-2018 and $4.077 billion for the full year 2018, the Tarryto...

2/21/2020
BreakingOphthalmicPharmaRetina
Novartis’ Beovu Gains Approval in Europe for Wet AMD

Novartis announced Feb. 17 that its Beovu (brolucizumab) had received European Commission approval as a treatment for wet age-related macular degeneration. The approval is applicable to all 27 Euro...

2/21/2020
BreakingMeetingOphthalmicSurgical
Applications Open Now for Winning Pitch Challenge at ASCRS

The Winning Pitch Challenge is accepting submissions at WinningPitchChallenge.net for its next event, set for May 17 at the annual American Society of Cataract and Refractive Surgery (ASCRS) confer...

2/21/2020
BreakingDeviceEarningsOphthalmic
Carl Zeiss Meditec Continues Strong Growth Trend After Three Months of FY2019-2020

Carl Zeiss Meditec reported Feb. 10 that revenue for its Ophthalmic Devices strategic business unit in the first three months of fiscal year 2019-2020 totaled $290.8 million (€269.4 million), an in...

2/21/2020
BreakingFundingGene TherapyOphthalmic
AGTC Announces Pricing of $32.5 Million Public Offering

Applied Genetic Technologies Corporation (AGTC) announced Feb. 6 that it had priced its underwritten public offering of 6.5 million shares of common stock at $5 per share, less underwriting discoun...

Past News Stories

2/21/2020
AllergyNewsletterOphthalmicPharmaRegulation
Alcon Gains FDA Approval of OTC Pataday Through Rx-to-OTC Switch

Alcon will launch two versions of nonprescription Pataday on March 2 in the US after gaining FDA approval Feb. 14. The company’s spinoff from Novartis in 2019 included the rights to switch specifie...

2/21/2020
CataractDevice ChinaIOLNewsletterOphthalmic
Coronavirus Will Cause Reduction in Cataract Surgeries in China

Market Scope expects a sharp drop in cataract surgeries in the first quarter of 2019 in Hubei province in China. Hubei is the province where the coronavirus epidemic started. More than 50 thousand ...

2/21/2020
NewsletterOphthalmicPharmaRegulation
FDA Approves Horizon’s Tepezza, First Drug for Thyroid Eye Disease

The US FDA has approved Horizon Therapeutics’ teprotumumab for the treatment of thyroid eye disease (TED). The drug, branded Tepezza, was approved Jan. 21. It is the first drug approved for the tre...

2/21/2020
NewsletterOphthalmicPharmaRegulationRetina
Novartis’ Beovu Gains Approval in Europe for Treatment of Patients with Wet AMD

Novartis announced Feb. 17 that its Beovu (brolucizumab) had received European Commission approval as a treatment for wet age-related macular degeneration (AMD). The approval is applicable to all 2...

2/21/2020
LaserNewsletterOphthalmic
PDL BioPharma, Parent of LENSAR, Markets Assets in ‘Wind-Down Monetization’

PDL BioPharma, parent of LENSAR, is exploring a variety of potential transactions, including a sale of PDL, divestiture of its assets, a spinoff, or merger, as it executes a “wind-down monetization...

2/21/2020
FundingNewsletterOphthalmic
Beam Leads Latest Fundraising Efforts with $207 Million IPO

Beam Therapeutics, of Cambridge, Massachusetts, led recent fundraising efforts by ophthalmic companies. The gene therapy company raised $207 million in an initial public offering, nearly twice the ...

2/21/2020
DeviceNewsletterOphthalmic
Artificial Iris Receives Transitional Pass-Through Payment Status

VEO Ophthalmics, of Cincinnati, announced Jan. 14 that the Customflex ArtificialIris had been approved by the Centers for Medicare and Medicaid Services (CMS) for transitional pass-through payment ...

2/21/2020
DeviceNewsletterOphthalmic
Santen, Verily Establish Joint Venture to Develop Ophthalmic Devices

Santen Pharmaceutical and Alphabet’s life sciences subsidiary Verily announced Feb. 4 that they had teamed up to focus on applying microelectronics and scalable digital technologies to ophthalmolog...

2/21/2020
Dry EyeNewsletterOphthalmicPharmaRetina
Emerging Companies Pursuing Ophthalmic Indications, February 2020

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About Viela Bio Gaithersburg, Maryland The company announced Dec. 11 that t...

2/21/2020
Clinical TrialNewsletterOphthalmic
Market Scope Weekly Ophthalmic Surgeon Poll for February 2020

2/21/2020
DeviceNewsletterOphthalmicPharma
February 2020 Ophthalmic News Briefs

Aerie Pharmaceuticals announced Jan. 21 that its sterile fill production facility in Athlone, Ireland, had received approval from US Food and Drug Administration (FDA) to produce its glaucoma drug ...

2/19/2020
OphthalmicPress ReleaseRetina
Expanding Product Needs, Surgery Growth Will Drive Retinal Surgical Device Market to Nearly $2 Billion by 2025

Ophthalmologists use more specialized products in retinal surgeries than other subspecialties, producing more revenue per procedure than segments with higher surgical volume. As a result, the retin...

Want to Read the Full Article?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 201 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2020 Market Scope, LLC. All Rights reserved.